BidaskClub lowered shares of Regenxbio (NASDAQ:RGNX) from a strong-buy rating to a buy rating in a report issued on Tuesday morning.
Several other equities research analysts have also issued reports on the company. Raymond James Financial reissued a buy rating on shares of Regenxbio in a research note on Friday, January 5th. Chardan Capital reissued a buy rating on shares of Regenxbio in a research note on Monday, December 11th. TheStreet lowered Regenxbio from a c rating to a d+ rating in a research note on Tuesday, November 28th. Barclays assumed coverage on Regenxbio in a research note on Wednesday, November 22nd. They set an overweight rating and a $38.00 price objective for the company. Finally, Zacks Investment Research lowered Regenxbio from a buy rating to a hold rating in a research note on Friday, November 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $42.43.
Regenxbio (NASDAQ RGNX) traded up $0.55 during trading hours on Tuesday, reaching $30.45. The company had a trading volume of 642,016 shares, compared to its average volume of 749,924. The company has a market capitalization of $935.92 and a price-to-earnings ratio of -11.24. Regenxbio has a 12 month low of $16.30 and a 12 month high of $36.45.
Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.04. The company had revenue of $1.34 million during the quarter. Regenxbio had a negative return on equity of 40.88% and a negative net margin of 1,549.85%. research analysts anticipate that Regenxbio will post -2.71 EPS for the current year.
In other Regenxbio news, SVP Curran Simpson sold 2,000 shares of Regenxbio stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $29.31, for a total transaction of $58,620.00. Following the completion of the sale, the senior vice president now owns 41,500 shares of the company’s stock, valued at $1,216,365. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Vittal Vasista sold 5,000 shares of Regenxbio stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $33.25, for a total value of $166,250.00. Following the sale, the chief financial officer now directly owns 92,283 shares of the company’s stock, valued at approximately $3,068,409.75. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 94,000 shares of company stock valued at $2,947,446. Corporate insiders own 17.00% of the company’s stock.
A number of hedge funds have recently modified their holdings of RGNX. Schwab Charles Investment Management Inc. lifted its stake in Regenxbio by 32.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 97,695 shares of the biotechnology company’s stock worth $1,930,000 after purchasing an additional 23,971 shares during the last quarter. Rhumbline Advisers lifted its stake in Regenxbio by 45.5% during the second quarter. Rhumbline Advisers now owns 27,251 shares of the biotechnology company’s stock worth $538,000 after purchasing an additional 8,520 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in Regenxbio during the second quarter worth about $415,000. Bank of New York Mellon Corp lifted its stake in Regenxbio by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 177,277 shares of the biotechnology company’s stock worth $3,501,000 after purchasing an additional 30,725 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in Regenxbio by 41.4% during the second quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 2,011 shares during the last quarter. 68.73% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “BidaskClub Lowers Regenxbio (RGNX) to Buy” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/01/12/bidaskclub-lowers-regenxbio-rgnx-to-buy.html.
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.